[关键词]
[摘要]
目的 观察五酯胶囊联合替诺福韦酯治疗慢性乙型肝炎的临床疗效。方法 选取2018年1月-2018年12月东部战区总医院收治106例患者,随机分为对照组和治疗组,每组各53例。对照组口服口服富马酸替诺福韦二吡呋酯片,300 mg/次,1次/d;治疗组在对照组治疗基础上口服五酯胶囊,2粒/次,3次/d。两组均连续治疗12周。观察两组的临床疗效,比较两组治疗前后丙氨酸氨基转氨酶(ALT)、门冬氨酸氨基转氨酶(AST)、白细胞介素-17(IL-17)、白细胞介素-22(IL-22)、乙肝病毒基因(HBV-DNA)的变化情况。结果 治疗后,对照组和治疗组的总有效率分别是69.81%、88.68%,两组比较差异有统计学意义(P<0.05)。治疗后,两组ALT、AST、IL-17、IL-22、HBV-DNA均较治疗前显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组这些指标显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论 五酯胶囊联合替诺福韦酯治疗慢性乙型肝炎临床疗效确切,化验指标改善明显,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To observe the clinical efficacy of Wuzhi Capsules combined with tenofovir dipivoxil in treatment of chronic hepatitis B. Methods 106 Patients with chronic hepatitis B in Eastern Theater General Hospital from January 2018 to December 2018 were randomly divided into control and treatment groups, and each group has 53 cases. Patients in the control group were po administered with Tenofovir Disoproxil Fumarate Tablets, 300 mg/time, once daily. Patients in the treatment group were po administered with Wuzhi Capsules on the basis of the control group. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of ALT, AST, IL-17, IL-22, and HBV-DNA in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 69.81% and 88.68%, respectively, and there were differences between two groups (P<0.05). After treatment, ALT, AST, IL-17, IL-22, and HBV-DNA in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the indicators in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Wuzhi Capsules combined with tenofovir dipivoxil has significant effect in treatment of chronic hepatitis B, and the laboratory indicators improved significantly, which has a certain clinical application value.
[中图分类号]
[基金项目]